Seminars in Fetal & Neonatal Medicine
Volume 12, Issue 4 , Pages 296-302 , August 2007

Anti-inflammatory and immunomodulatory strategies to protect the perinatal brain

  • Adam J. Wolfberg

      Affiliations

    • Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Tufts New England Medical Center, Boston, MA, USA
    • ,
  • Olaf Dammann

      Affiliations

    • Division of Newborn Medicine, Tufts-New England Medical Center, Boston, MA, USA
    • Perinatal ID Epidemiology Unit, Departments of Pediatrics and Gynecology/Obstetrics, Hannover Medical School, Hannover, Germany
    • Neuroepidemiology Unit, Department of Neurology, Children's Hospital and Harvard Medical School, Boston, MA, USA
    • ,
  • Pierre Gressens

      Affiliations

    • Inserm, U676, Paris, France
    • Université Paris 7, Faculté de Médecine Denis Diderot, IFR02 and IFR25, Paris, France
    • AP HP, Hôpital Robert Debré, Service de Neurologie Pédiatrique, Paris, France
    • Corresponding Author InformationCorresponding author. INSERM U676, Hôpital Robert Debré, 48 Blvd. Sérurier, F-759019 Paris, France. Tel.: +33 (0)1 40 03 19 76; fax +33 (0)1 40 03 19 95.

References 

  1. Dammann O, Leviton A. Inflammatory brain damage in preterm newborns—dry numbers, wet lab, and causal inferences. Early Hum Dev. 2004;79(1):1–15
  2. Wu YW. Systematic review of chorioamnionitis and cerebral palsy. Ment Retard Dev Disabil Res Rev. 2002;8(1):25–29
  3. Leviton A, Paneth N, Reuss ML, et al. Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants. Developmental Epidemiology Network Investigators. Pediatr Res. 1999;46(5):566–575
  4. Yoon B, Romero R, Park J, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol. 2000;182:675–681
  5. Duggan PJ, Maalouf EF, Watts TL, et al. Intrauterine T-cell activation and increased proinflammatory cytokine concentrations in preterm infants with cerebral lesions. Lancet. 2001;358(9294):1699–1700
  6. Young RS, Hernandez MJ, Yagel SK. Selective reduction of blood flow to white matter during hypotension in newborn dogs: a possible mechanism of periventricular leukomalacia. Ann Neurol. 1982;12(5):445–448
  7. Yoon B, Kim C, Romero R, et al. Experimentally induced intrauterine infection causes fetal brain white matter lesions in rabbits. Am J Obstet Gynecol. 1997;177:797–802
  8. Bell MJ, Hallenbeck JM. Effects of intrauterine inflammation on developing rat brain. J Neurosci Res. 2002;70(4):570–579
  9. Duncan JR, Cock ML, Scheerlinck JP, et al. White matter injury after repeated endotoxin exposure in the preterm ovine fetus. Pediatr Res. 2002;52(6):941–949
  10. Pang Y, Cai Z, Rhodes PG. Disturbance of oligodendrocyte development, hypomyelination and white matter injury in the neonatal rat brain after intracerebral injection of lipopolysaccharide. Brain Res Dev Brain Res. 2003;140(2):205–214
  11. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol. 2000;107(2):161–166
  12. du Plessis AJ, Volpe JJ. Perinatal brain injury in the preterm and term newborn. Curr Opin Neurol. 2002;15(2):151–157
  13. Dordelmann M, Kerk J, Dressler F, et al. Interleukin-10 high producer allele and ultrasound-defined periventricular white matter abnormalities in preterm infants: a preliminary study. Neuropediatrics. 2006;37(3):130–136
  14. Redline RW. Inflammatory responses in the placenta and umbilical cord. Semin Fetal Neonat Med. 2006;11(5):296–301
  15. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel LA, Nien JK. Inflammation in preterm and term labour and delivery. Semin Fetal Neonat Med. 2006;11(5):317–326
  16. Watterberg K. Anti-inflammatory therapy in the neonatal intensive care unit: present and future. Semin Fetal Neonat Med. 2006;11(5):378–384
  17. Elovitz MA. Anti-inflammatory interventions in pregnancy: now and the future. Semin Fetal Neonat Med. 2006;11(5):327–332
  18. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–305
  19. Dammann O. Danger: hydra in wonderland!. Semin Fetal Neonat Med. 2006;11(5):277–278
  20. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147(Suppl. 1):S232–S240
  21. Grotenhermen F. Cannabinoids. Curr Drug Targets. 2005;4(5):507–530
  22. Shouman B, Fontaine RH, Baud O, et al. Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. Br J Pharmacol. 2006;148(4):442–451
  23. Eljaschewitsch E, Witting A, Mawrin C, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron. 2006;49(1):67–79
  24. Follett PL, Deng W, Dai W, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci. 2004;24(18):4412–4420
  25. Sfaello I, Baud O, Arzimanoglou A, Gressens P. Topiramate prevents excitotoxic damage in the newborn rodent brain. Neurobiol Dis. 2005;20(3):837–848
  26. Schubert S, Brandl U, Brodhun M, et al. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res. 2005;1058(1–2):129–136
  27. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54(5):1559–1565
  28. Cai Z, Lin S, Fan LW, Pang Y, Rhodes PG. Minocycline alleviates hypoxic-ischemic injury to developing oligodendrocytes in the neonatal rat brain. Neuroscience. 2006;137(2):425–435
  29. Fan LW, Pang Y, Lin S, Rhodes PG, Cai Z. Minocycline attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neuroscience. 2005;133(1):159–168
  30. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002;52(1):54–61
  31. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005;94(3):819–827
  32. Jiang SX, Lertvorachon J, Hou ST, et al. Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia. J Biol Chem. 2005;280(40):33811–33818
  33. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist. 2005;11(4):308–322
  34. Dommergues MA, Plaisant F, Verney C, Gressens P. Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience. 2003;121(3):619–628
  35. Tsuji M, Wilson MA, Lange MS, Johnston MV. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp Neurol. 2004;189(1):58–65
  36. Li Y, Takemura G, Okada H, et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res. 2006;71(4):684–694
  37. Dzietko M, Felderhoff-Mueser U, Sifringer M, et al. Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis. 2004;15(2):177–187
  38. Zhang F, Wang S, Cao G, Gao Y, Chen J. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol Dis. 2007;25:45–53
  39. Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke. 2005;36(8):1672–1678
  40. Aida Y, Maeno M, Suzuki N, et al. The effect of IL-1beta on the expression of inflammatory cytokines and their receptors in human chondrocytes. Life Sci. 2006;79(8):764–771
  41. Emsley HC, Smith CJ, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76(10):1366–1372
  42. Pinteaux E, Rothwell NJ, Boutin H. Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia. 2006;53(5):551–556
  43. Molina-Holgado E, Arevalo-Martin A, Castrillo A, Bosca L, Vela JM, Guaza C. Interleukin-4 and interleukin-10 modulate nuclear factor kappaB activity and nitric oxide synthase-2 expression in Theiler's virus-infected brain astrocytes. J Neurochem. 2002;81(6):1242–1252
  44. Froen JF, Munkeby BH, Stray-Pedersen B, Saugstad OD. Interleukin-10 reverses acute detrimental effects of endotoxin-induced inflammation on perinatal cerebral hypoxia-ischemia. Brain Res. 2002;942(1–2):87–94
  45. Mesples B, Plaisant F, Gressens P. Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice. Brain Res Dev Brain Res. 2003;141(1–2):25–32
  46. Rodts-Palenik S, Wyatt-Ashmead J, Pang Y, et al. Maternal infection-induced white matter injury is reduced by treatment with interleukin-10. Am J Obstet Gynecol. 2004;191(4):1387–1392
  47. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA. 2006;103(12):4628–4633
  48. Beloosesky R, Gayle DA, Amidi F, et al. N-acetyl-cysteine suppresses amniotic fluid and placenta inflammatory cytokine responses to lipopolysaccharide in rats. Am J Obstet Gynecol. 2006;194(1):268–273
  49. Paintlia MK, Paintlia AS, Barbosa E, Singh I, Singh AK. N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J Neurosci Res. 2004;78(3):347–361
  50. Beloosesky R, Gayle DA, Ross MG. Maternal N-acetylcysteine suppresses fetal inflammatory cytokine responses to maternal lipopolysaccharide. Am J Obstet Gynecol. 2006;195(4):1053–1057
  51. Sunday L, Tran MM, Krause DN, Duckles SP. Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol. 2006;291(2):E261–E267
  52. Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, Voskuhl RR. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci. 2006;26(25):6823–6833
  53. Capellino S, Montagna P, Villaggio B, et al. Role of estrogens in inflammatory response: expression of estrogen receptors in peritoneal fluid macrophages from endometriosis. Ann NY Acad Sci. 2006;1069:263–267
  54. Husson I, Mesples B, Bac P, Vamecq J, Evrard P, Gressens P. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann Neurol. 2002;51(1):82–92
  55. Welin A, Svedin P, Laptto R, et al. Melatonin reduces inflammation and cell death in white matter in the 0.65 gestation fetal sheep following umbilical cord occlusion. Pediatr Res. 2007;61(2):153–158
  56. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27(2):189–200
  57. Plaisant F, Dommergues MA, Spedding M, et al. Neuroprotective properties of tianeptine: interactions with cytokines. Neuropharmacology. 2003;44(6):801–809
  58. McEwen BS, Olie JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry. 2005;10(6):525–537
  59. Solaroglu I, Cahill J, Jadhav V, Zhang JH. A novel neuroprotectant granulocyte-colony stimulating factor. Stroke. 2006;37(4):1123–1128
  60. Keller M, Simbruner G, Gorna A, et al. Systemic application of granulocyte-colony stimulating factor and stem cell factor exacerbates excitotoxic brain injury in newborn mice. Pediatr Res. 2006;59(4 Pt 1):549–553
  61. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003;290(20):2669–2676
  62. Marret S, Gressens P, Gadisseux JF, Evrard P. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies. Dev Med Child Neurol. 1995;37(6):473–484
  63. Mittendorf R, Dammann O, Lee KS. Brain lesions in newborns exposed to high-dose magnesium sulfate during preterm labor. J Perinatol. 2006;26(1):57–63
  64. Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: Potential physiopathological implications. Arch Biochem Biophy. 2007;458(1):48–56
  65. Felszeghy K, Banisadr G, Rostene W, Nyakas C, Haour F. Dexamethasone downregulates chemokine receptor CXCR4 and exerts neuroprotection against hypoxia/ischemia-induced brain injury in neonatal rats. Neuroimmunomodulation. 2004;11(6):404–413
  66. Hagberg H, Jacobsson B. Brain injury in preterm infants—what can the obstetrician do?. Early Hum Dev. 2005;81(3):231–235
  67. Baud O. Postnatal steroid treatment and brain development. Arch Dis Child Fetal Neonatal Ed. 2004;89(2):F96–F100
  68. Tutak E, Satar M, Zorludemir S, Erdogan S, Yapicioglu H, Narli N. Neuroprotective effects of indomethacin and aminoguanidine in the newborn rats with hypoxic-ischemic cerebral injury. Neurochem Res. 2005;30(8):937–942
  69. Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy. 2005;4(3):335–340
  70. Park EM, Cho BP, Volpe BT, Cruz MO, Joh TH, Cho S. Ibuprofen protects ischemia-induced neuronal injury via up-regulating interleukin-1 receptor antagonist expression. Neuroscience. 2005;132(3):625–631
  71. Favrais G, Schwendimann L, Gressens P, Lelievre V. Cyclooxigenase-2 mediates the sensitizing effects of systemic IL-1β on excitotoxic brain lesions in newborn mice. Neurobiol Dis. 2007;25(3):496–505
  72. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature. 1998;393(6680):83–85
  73. Viehover A, Miller RH, Park SK, Fischbach G, Vartanian T. Neuregulin: an oligodendrocyte growth factor absent in active multiple sclerosis lesions. Dev Neurosci. 2001;23(4–5):377–386
  74. Xu Z, Jiang J, Ford G, Ford BD. Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem Biophys Res Commun. 2004;322(2):440–446
  75. Xu Z, Ford BD. Upregulation of erbB receptors in rat brain after middle cerebral arterial occlusion. Neurosci Lett. 2005;375(3):181–186
  76. Xu Z, Croslan DR, Harris AE, Ford GD, Ford BD. Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke. J Cereb Blood Flow Metab. 2006;26:527–535
  77. Xu Z, Ford GD, Croslan DR, et al. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis. 2005;19(3):461–470
  78. Fisher CJJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein. N Engl J Med. 1996;334(26):1697–1702
  79. Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet. 1997;350(9090):1517–1518
  80. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol. 1993;151(3):1473–1481
  81. Dammann O, Leviton A. Brain damage in preterm newborns: might enhancement of developmentally regulated endogenous protection open a door for prevention?. Pediatrics. 1999;104(3 Pt 1):541–550
  82. Zhou X, Schmidtke P, Zepp F, Meyer CU. Boosting interleukin-10 production: therapeutic effects and mechanisms. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(4):465–475
  83. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA. 2005;293(16):2003–2011
  84. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause (New York). 2006;13(4):643–650
  85. Sunday LN, Tran MM, Krause DN, Duckles SP. Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab. 2006;291:E261–E267
  86. Bauhofer A, Lorenz W, Kohlert F, Torossian A. Granulocyte colony-stimulating factor prophylaxis improves survival and inflammation in a two-hit model of hemorrhage and sepsis. Crit Care Med. 2006;34(3):778–784
  87. Lu CZ, Xiao BG. G-CSF and neuroprotection: a therapeutic perspective in cerebral ischaemia. Biochem Soc Trans. 2006;34(Pt 6):1327–1333

PII: S1744-165X(07)00022-4

doi: 10.1016/j.siny.2007.01.021

Seminars in Fetal & Neonatal Medicine
Volume 12, Issue 4 , Pages 296-302 , August 2007

Article Tools